Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals

202324 citationsJournal Articlehybrid Open Access

Authors

Saad I. Mallah · Royal College of Surgeons in Ireland - Bahrain

Abdulla Alawadhi · Bahrain Center for Strategic International and Energy Studies

Jaleela S. Jawad · Bahrain Center for Strategic International and Energy Studies

Pearl Wasif · Royal College of Surgeons in Ireland - Bahrain

Basma Alsaffar · Ministry of Health

Ejlal Alalawi · Ministry of Health

Afaf Mohamed

Abstract

Heterologous prime-boost vaccination with the mRNA BNT162b2 (Pfizer) vaccine in those who had received two doses of inactivated virus BBIBP-CorV (Sinopharm) vaccine demonstrated a more robust immune response against SARS-CoV-2 than the homologous BBIBP booster and appears safe and well tolerated. Clinical Trial Registry Number (ClinicalTrials.gov): NCT04993560.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Viral gastroenteritis research and epidemiology Animal Virus Infections Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Vaccine

Volume 41, Issue 12, pp. 1925-1933

DOI: 10.1016/j.vaccine.2023.01.032

Field-Weighted Citation Impact: 4.67